Charles River Analyst Ratings
Charles River Analyst Ratings
Charles River Analyst Ratings
TD Cowen: Maintaining the Charles River (CRL.US) rating, adjusted from holding to holding rating, and adjusted the target price from $260.00 to $228.00.
Charles River Analyst Ratings
TD Cowen Adjusts Price Target on Charles River Laboratories International to $228 From $260
Charles Rhyee Maintains Hold on Charles River Labs Amidst Revenue and Market Uncertainties
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)
Charles River Analyst Ratings
Baird Adjusts Price Target on Charles River Laboratories International to $270 From $282
Buy Rating on Charles River Labs Amidst Solid Q1 Performance and Positive Market Outlook
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Charles River Labs (CRL) and Neurocrine (NBIX)
Zacks Investment Research Adjusts Charles River Laboratories International's Price Target to $259 From $278
Deutsche Bank Raises Price Target on Charles River Laboratories to $300 From $275, Keeps Buy Rating
Charles River Analyst Ratings
Morgan Stanley Raises Price Target on Charles River Laboratories International to $235 From $205, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Charles River Labs (CRL) and Shockwave Medical (SWAV)
Evercore ISI Remains a Buy on Charles River Labs (CRL)
Baird Adjusts Price Target on Charles River Laboratories International to $268 From $252, Maintains Outperform Rating
Charles River Analyst Ratings